Halifax, Canada
Halifax, Canada
SEARCH FILTERS
Time filter
Source Type

LONDON, UK / ACCESSWIRE / April 26, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Cardiome Pharma, Immunovaccine, Oncolytics Biotech, and Aeterna Zentaris. Get all of our free research reports by signing up at: At the close of the Canadian markets on Tuesday, April 25, 2017, the Toronto Exchange Composite index ended the trading session at 15,745.19, 0.21% higher from its previous closing price. The Healthcare Index was also in the black, closing the day at 63.59, up 0.38%. Active Wall St. has initiated research reports on the following equities: Cardiome Pharma Corporation (TSX: COM), Immunovaccine Inc. (TSX: IMV), Oncolytics Biotech Inc. (TSX: ONC), and Aeterna Zentaris Inc. (TSX: AEZS). Register with us now for your free membership and research reports at: Vancouver, Canada headquartered Cardiome Pharma Corp.'s stock advanced 1.87%, to finish Tuesday's session at $4.35 with a total volume of 19,350 shares traded. Over the last one month and the previous three months, Cardiome Pharma's shares have gained 6.10% and 13.28%, respectively. Shares of the Company, which engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases, are trading above its 50-day and 200-day moving averages. Cardiome Pharma's 50-day moving average of $4.11 is above its 200-day moving average of $3.89. See our research report on COM.TO at: On Tuesday, shares in Halifax, Canada headquartered Immunovaccine Inc. recorded a trading volume of 687,080 shares, which was above their three months average volume of 228,959 shares. The stock ended the day 6.67% higher at $1.28. Immunovaccine's stock has surged 6.67% in the last one month and 82.86% in the previous three months. Furthermore, the stock has rallied 93.94% in the past one year. Shares of the Company, whch develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $1.17 is above its 200-day moving average of $0.91. The complimentary research report on IMV.TO at: On Tuesday, shares in Calgary, Canada headquartered Oncolytics Biotech Inc. ended the session 1.04% lower at $0.95 with a total volume of 255,382 shares traded. Oncolytics Biotech's shares have surged 58.33% in the last one month, 251.85% in the previous three months and 58.33% in the past one year. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 50-day moving average of $0.70 is greater than its 200-day moving average of $0.39. Register for free and access the latest research report on ONC.TO at: Summerville, South Carolina headquartered Aeterna Zentaris Inc.'s stock closed the day 1.22% higher at $4.14. The stock recorded a trading volume of 9,860 shares. Aeterna Zentaris' shares have advanced 3.24% in the last one month and 21.05% in the past three months. Shares of the Company, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.06 is greater than its 50-day moving average of $3.96. Get free access to your research report on AEZS.TO at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / April 26, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Cardiome Pharma, Immunovaccine, Oncolytics Biotech, and Aeterna Zentaris. Get all of our free research reports by signing up at: At the close of the Canadian markets on Tuesday, April 25, 2017, the Toronto Exchange Composite index ended the trading session at 15,745.19, 0.21% higher from its previous closing price. The Healthcare Index was also in the black, closing the day at 63.59, up 0.38%. Active Wall St. has initiated research reports on the following equities: Cardiome Pharma Corporation (TSX: COM), Immunovaccine Inc. (TSX: IMV), Oncolytics Biotech Inc. (TSX: ONC), and Aeterna Zentaris Inc. (TSX: AEZS). Register with us now for your free membership and research reports at: Vancouver, Canada headquartered Cardiome Pharma Corp.'s stock advanced 1.87%, to finish Tuesday's session at $4.35 with a total volume of 19,350 shares traded. Over the last one month and the previous three months, Cardiome Pharma's shares have gained 6.10% and 13.28%, respectively. Shares of the Company, which engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases, are trading above its 50-day and 200-day moving averages. Cardiome Pharma's 50-day moving average of $4.11 is above its 200-day moving average of $3.89. See our research report on COM.TO at: On Tuesday, shares in Halifax, Canada headquartered Immunovaccine Inc. recorded a trading volume of 687,080 shares, which was above their three months average volume of 228,959 shares. The stock ended the day 6.67% higher at $1.28. Immunovaccine's stock has surged 6.67% in the last one month and 82.86% in the previous three months. Furthermore, the stock has rallied 93.94% in the past one year. Shares of the Company, whch develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $1.17 is above its 200-day moving average of $0.91. The complimentary research report on IMV.TO at: On Tuesday, shares in Calgary, Canada headquartered Oncolytics Biotech Inc. ended the session 1.04% lower at $0.95 with a total volume of 255,382 shares traded. Oncolytics Biotech's shares have surged 58.33% in the last one month, 251.85% in the previous three months and 58.33% in the past one year. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 50-day moving average of $0.70 is greater than its 200-day moving average of $0.39. Register for free and access the latest research report on ONC.TO at: Summerville, South Carolina headquartered Aeterna Zentaris Inc.'s stock closed the day 1.22% higher at $4.14. The stock recorded a trading volume of 9,860 shares. Aeterna Zentaris' shares have advanced 3.24% in the last one month and 21.05% in the past three months. Shares of the Company, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.06 is greater than its 50-day moving average of $3.96. Get free access to your research report on AEZS.TO at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / April 26, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Cardiome Pharma, Immunovaccine, Oncolytics Biotech, and Aeterna Zentaris. Get all of our free research reports by signing up at: At the close of the Canadian markets on Tuesday, April 25, 2017, the Toronto Exchange Composite index ended the trading session at 15,745.19, 0.21% higher from its previous closing price. The Healthcare Index was also in the black, closing the day at 63.59, up 0.38%. Active Wall St. has initiated research reports on the following equities: Cardiome Pharma Corporation (TSX: COM), Immunovaccine Inc. (TSX: IMV), Oncolytics Biotech Inc. (TSX: ONC), and Aeterna Zentaris Inc. (TSX: AEZS). Register with us now for your free membership and research reports at: Vancouver, Canada headquartered Cardiome Pharma Corp.'s stock advanced 1.87%, to finish Tuesday's session at $4.35 with a total volume of 19,350 shares traded. Over the last one month and the previous three months, Cardiome Pharma's shares have gained 6.10% and 13.28%, respectively. Shares of the Company, which engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases, are trading above its 50-day and 200-day moving averages. Cardiome Pharma's 50-day moving average of $4.11 is above its 200-day moving average of $3.89. See our research report on COM.TO at: On Tuesday, shares in Halifax, Canada headquartered Immunovaccine Inc. recorded a trading volume of 687,080 shares, which was above their three months average volume of 228,959 shares. The stock ended the day 6.67% higher at $1.28. Immunovaccine's stock has surged 6.67% in the last one month and 82.86% in the previous three months. Furthermore, the stock has rallied 93.94% in the past one year. Shares of the Company, whch develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $1.17 is above its 200-day moving average of $0.91. The complimentary research report on IMV.TO at: On Tuesday, shares in Calgary, Canada headquartered Oncolytics Biotech Inc. ended the session 1.04% lower at $0.95 with a total volume of 255,382 shares traded. Oncolytics Biotech's shares have surged 58.33% in the last one month, 251.85% in the previous three months and 58.33% in the past one year. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 50-day moving average of $0.70 is greater than its 200-day moving average of $0.39. Register for free and access the latest research report on ONC.TO at: Summerville, South Carolina headquartered Aeterna Zentaris Inc.'s stock closed the day 1.22% higher at $4.14. The stock recorded a trading volume of 9,860 shares. Aeterna Zentaris' shares have advanced 3.24% in the last one month and 21.05% in the past three months. Shares of the Company, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.06 is greater than its 50-day moving average of $3.96. Get free access to your research report on AEZS.TO at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report. 1: Introduction - Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown 3: Overview - Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology 4: Overview of Cancer Immunotherapy - Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications 7: Company Profiles - Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd. For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html


Company's Clinical Program Continues to Expand with Second Phase 2 Trial Announced This Year Evaluating the Combination of DPX-Survivac and Anti-PD-1 Therapies in Hard-to-Treat Cancers HALIFAX, NOVA SCOTIA--(Marketwired - May 16, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced that an investigator-sponsored Phase 2 clinical trial will evaluate the use of a triple-combination immunotherapy in patients with measurable or recurrent diffuse large B-Cell lymphoma (DLBCL). Investigators will assess the efficacy and safety of Immunovaccine's lead candidate, DPX-Survivac, along with a checkpoint inhibitor drug currently marketed by a large pharmaceutical company, and low-dose cyclophosphamide. Immunovaccine expects the trial to begin enrolling patients following receipt of regulatory clearance from Health Canada. "While immunotherapies, such as checkpoint inhibitors, are rapidly changing the standard of care in many cancers, it has been reported that only about 20 percent of patients are able to respond to these therapies alone, leaving the vast majority of patients with a significant unmet medical need," said Frederic Ors, Chief Executive Officer at Immunovaccine.i "Our clinical strategy builds on our earlier research, which indicated that novel combination immunotherapies-particularly those with the ability to increase T-cell tumor infiltration-may work together synergistically to increase the number of patients responding to today's advanced treatments. We remain committed to working with world-class partners to bring these combinations through clinical development. Our goal is to generate more therapeutic options for patients currently underserved in today's treatment landscape." Researchers conducting the investigator-sponsored study will test the novel immunotherapy combination in patients whose DLBCL expresses survivin, a tumor antigen highly expressed in 60 percent of DLBCL patients. DPX-Survivac stimulates the immune system to produce T cell responses targeting survivin. The non-randomized, open-label study is expected to enroll 25 evaluable participants at five centers in Canada. This clinical trial is the third ongoing triple-combination study using DPX-Survivac with low-dose cyclophosphamide and other immuno-modulating agents. The Company announced earlier this year that an investigator-sponsored Phase 2 study will evaluate the anti-tumor activity of Merck's pembrolizumab with DPX-Survivac and cyclophosphamide in patients with recurrent, platinum-resistant ovarian cancer. In addition, Immunovaccine recently released positive early data from its Phase 1b triple-combination trial with Incyte Corporation, evaluating DPX-Survivac, low-dose cyclophosphamide and Incyte's IDO1 inhibitor epacadostat in patients with recurrent ovarian cancer. Advanced analysis of one of the patients in Immunovaccine's initial Phase 2 study in DLBCL patients provided a strong rationale for this novel triple combination. Early data indicated that there was a correlation between immune response and tumor changes following administration of DPX-Survivac. Specifically: Based on these findings, and to bring the clinical program in line with Immunovaccine strategy of focusing its immuno-oncology pipeline on combinations with checkpoint inhibitors, Immunovaccine has elected to conclude operations on its initial Phase 2 DLBCL study, opting to replace it with this triple-combination trial. According to the Lymphoma Research Foundation, diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for up to one-third of patients with newly diagnosed NHL in the United States. Although it can occur in childhood, the occurrence of DLBCL generally increases with age, and most patients are over the age of 60 at diagnosis. DLBCL is an aggressive NHL that affects B-lymphocytes and can spread to sites outside the lymphatic system, such as the gastrointestinal tract, testes, thyroid, skin, breast, bone, brain, or essentially any organ of the body. DPX-Survivac consists of survivin-based peptide antigens formulated in the Company's proprietary DepoVax™ delivery platform. DPX-Survivac is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides. Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to anti-cancer therapies. Immunovaccine has identified over 15 cancer indications in which the over-expression of survivin can be targeted by DPX-Survivac. DPX-Survivac received Fast Track designation from the U.S. Food & Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA). Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com. This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. i Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok. Combination immunotherapy: a road map. Journal for ImmunoTherapy of Cancer (2017). 5:16 DOI 10.1186/s40425-017-0218-5

Loading Immunovaccine collaborators
Loading Immunovaccine collaborators